GILEAD Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GILEAD, and when can generic versions of GILEAD drugs launch?
GILEAD has thirty approved drugs.
There are eighty-eight US patents protecting GILEAD drugs.
There are two thousand three hundred and twenty-three patent family members on GILEAD drugs in sixty-six countries and three hundred and ninety-seven supplementary protection certificates in nineteen countries.
Summary for GILEAD
International Patents: | 2323 |
US Patents: | 88 |
Tradenames: | 24 |
Ingredients: | 24 |
NDAs: | 30 |
Patent Litigation for GILEAD: | See patent lawsuits for GILEAD |
PTAB Cases with GILEAD as patent owner: | See PTAB cases with GILEAD as patent owner |
Drugs and US Patents for GILEAD
Expired US Patents for GILEAD
Paragraph IV (Patent) Challenges for GILEAD drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 200 mg/25 mg/300 mg | ➤ Subscribe | 2015-05-20 |
➤ Subscribe | Tablets | 150 mg | ➤ Subscribe | 2015-12-09 |
➤ Subscribe | Tablets | 10 mg | ➤ Subscribe | 2010-06-08 |
➤ Subscribe | Tablets | 200 mg/300 mg | ➤ Subscribe | 2008-09-26 |
➤ Subscribe | Tablets | 600 mg/200 mg/300 mg | ➤ Subscribe | 2008-12-29 |
➤ Subscribe | Tablets | 150 mg, 200 mg, and 250 mg | ➤ Subscribe | 2012-05-17 |
➤ Subscribe | Tablets | 150 mg, 150 mg, 200 mg, 300 mg | ➤ Subscribe | 2018-10-04 |
➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2012-07-16 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2015-02-09 |
➤ Subscribe | Tablets | 100 mg/150 mg, 133 mg/200 mg, and 167 mg/250 mg | ➤ Subscribe | 2017-05-19 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2010-01-26 |
International Patents for GILEAD Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2021221855 | ⤷ Try a Trial |
Singapore | 10202109869X | ⤷ Try a Trial |
Brazil | PI0823519 | ⤷ Try a Trial |
Slovenia | 2709613 | ⤷ Try a Trial |
Chile | 2017001040 | ⤷ Try a Trial |
Taiwan | 200711652 | ⤷ Try a Trial |
Hong Kong | 1137451 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for GILEAD Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1761540 | 17C1007 | France | ⤷ Try a Trial | PRODUCT NAME: IDELALISIB OU SEL DE CELUI-CI ACCEPTABLE D'UN POINT DE VUE PHARMACEUTIQUE; REGISTRATION NO/DATE: EU/1/14/938 20140919 |
1761540 | 9/2017 | Austria | ⤷ Try a Trial | PRODUCT NAME: IDELALISIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/938 (MITTEILUNG) 20140919 |
2595980 | 132020000000176 | Italy | ⤷ Try a Trial | PRODUCT NAME: REMDESIVIR O SALE O ESTERE FARMACEUTICAMENTE ACCETTABILE DELLO STESSO(VEKLURY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1459, 20200703 |
2822954 | 330 16-2018 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: BIKTEGRAVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/18/1289 20180625 |
1564210 | PA2013018 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: ELVITEGRAVIRUM; REGISTRATION NO/DATE: EU/1/13/830/001, 2013 05 24 EU/1/13/830/002 20130524 |
2203462 | PA2014040,C2203462 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: SOFOSBUVIRAS; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116 |
2430014 | 16C0005 | France | ⤷ Try a Trial | PRODUCT NAME: LEDIPASVIR; REGISTRATION NO/DATE: EU/1/14/958/001-002 20141118 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.